SAN MATEO, Calif., Sept. 8, 2011 /PRNewswire/ — Nile
Therapeutics, Inc. (OTCQB: NLTX), a company focused on the
development of novel therapeutics for cardiovascular disease, today
announced that Daron Evans, Chief Financial Officer, will present
at the Rodman & Renshaw 13th Annual Global Investment
Conference on Tuesday, September 13, 2010 at 2:50 p.m. (Eastern
Time) at The Waldorf Astoria in New York City, New York..
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical
company that develops innovative products for the treatment of
cardiovascular disease and other areas of unmet medical needs. Nile
is initially focusing its efforts on developing its lead compound,
cenderitide, a novel rationally-designed chimeric peptide in
clinical studies for the treatment of heart failure. More
information on Nile can be found at http://www.nilethera.com.